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ABSTRACT
Epilepsy and Alzheimer’s disease are two prevalent neurological disorders. The blood-brain
barrier (BBB) is a factor in why there are no long-term treatments for these diseases. The
transporters in the neurovascular unit (NVU), which makes up the BBB, are highly specialized,
so most drugs cannot pass the barrier to treat these diseases. It is unknown why drug uptake in
the BBB varies in a diseased and wild-type brain, but one theory is that there are spatial
differences in the NVU. One method for examining the NVU is the CLARITY tissue clearing
technique which is unique in its capability to clear and image large quantities of tissue.
Developing and optimizing the methods for the CLARITY tissue clearing process, antibody
labeling, and imaging was the focus of this study. The images were quantitatively analyzed for
percentage area antibody staining and qualitatively analyzed for morphological differences in the
NVU.
INTRODUCTION
Significance of Research
Alzheimer’s disease and epilepsy are two common degenerative neurological disorders (Banks,
2012; Basic et al., 2008). There are no effective long-term treatments for these diseases, and this
is partially due to the blood-brain barrier’s (BBB) function. The BBB is the microvasculature of
the brain that regulates exchanges between blood in the circulatory system and the brain (Banks,
2012). Since regulation of the brain is its primary function, the transporters lining the BBB are
selective and only allow specific cells and compounds to cross the barrier into the brain (Banks,
2012).
As a result of the BBB’s specificity, drug delivery into the brain can be inhibited or
largely ineffective (Banks, 2012). For example, approximately 1/3 of epileptic patients
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experience seizures that cannot be managed with pharmacotherapy (Tang et al., 2017). There is a
hypothesis that specifically ATP-binding cassette (ABC) efflux transporters, which line the
capillaries of the BBB, likely contribute to drug delivery and uptake in epilepsy and Alzheimer’s
disease (Tang et al., 2017; Wijesuriya et al., 2010). These transporters protect the brain from
substances that are identified as potentially harmful and do not allow them to enter the brain
(Wijesuriya et al., 2010). Unfortunately, these transporters cannot distinguish between toxic
substances and therapeutic drugs, and therefore, prevent drug delivery into the brain (Wijesuriya
et al., 2010).
Drug trials often fail because either BBB inhibition is not considered or a disruption of
the BBB that is ineffective or would potentially allow neurotoxins to enter the brain is proposed
(Banks, 2012). Additionally, it has been established that drug uptake occurs differently in a brain
that is affected by Alzheimer’s disease or epilepsy and a wild-type brain (Banks, 2012; Basic et
al., 2008). One theory to explain the difference in drug uptake is that there are spatial differences
in the neurovascular unit (NVU). The NVU consists of four main components: astrocytes,
pericytes, neurons, and endothelial cells. Endothelial cells line the capillaries of the BBB, which
is where ABC efflux transporters are located (Hartz & Bauer, 2010).
Studying the spatial differences in the NVU between a wild-type brain and an epileptic
brain or an Alzheimer’s disease brain can further understanding of the differences in drug
uptake. The CLARITY tissue clearing and imaging process is one method for studying the
structure and function of the vasculature in the brain (Chung et al., 2013).
CLARITY Overview and Importance
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The CLARITY tissue clearing technique consists of 5
steps which can be seen in Figure 1 (Rodgers, 2017). The
incubation of brain tissue in hydrogel solution (step 1) is
to promote cross-linking of proteins which will allow the
tissue to retain its structure. The polymerization step (step
2) allows the smaller organic molecules in the brain to
come together, leaving the lipids unbound. The tissue
clearing step (step 3) removes lipids from brain tissue,
making the tissue visually transparent. The antibody
labeling step (step 4) uses an immunofluorescent marker
to stain the specific structures in the tissue needed for
analysis. The final imaging step (step 5) allows

Figure 1. Summary of the CLARITY tissue clearing process.
Modified according to a figure in Logos: X-CLARITY (Shin,
2018).

researchers to visualize and analyze the labeled

structures. Confocal microscopy is used for imaging because the wavelengths emitted by the
laser penetrate cleared tissue deeply (Chung & Deisseroth, 2013).
The CLARITY process is unique from other methods because it allows for large
quantities of tissues to be sectioned, cleared, and imaged without lysing or causing damage to the
structure of individual slices (Chung et al., 2013). Other current methods, such as a Western blot
or ELISA, involve lysing tissue or are limited to small amounts of intact tissue being
reconstructed (Chung et al., 2013). There is another established tissue clearing method, known as
3DISCO, but it would not be advantageous for this experiment because the dehydration process
can lead to tissue shrinkage, and this method leads to greater protein loss in the tissue (Azaripour
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et al., 2016). The CLARITY method allows for comprehensive information extraction by
preventing lysing of sectioned tissue during clearing (Chung et al., 2013).
Objectives and Hypothesis
The first objective of this study is to fully clear control and status epilepticus rat brains using the
CLARITY tissue clearing process. The second objective of this study is to image the
neurovascular unit using immunofluorescent antibody labeling and assess for potential
morphological differences. The hypothesis of this study is that using the methods developed in
this study allows the visualization of potential spatial differences in the neurovascular unit
between wild-type and epileptic rats using immunofluorescent labeling.
MATERIALS AND METHODS
Brain Preparation and Extraction
The rats from the control (CTRL) group and the status epilepticus (SE) group were euthanized
using Fatal Plus. The difference between these groups is that seizures were induced in the SE rats
using pilocarpine. SE is defined as continuous seizing for longer than 5 minutes (Wylie et al.,
2021). In this study, the rats were in SE for 90 minutes. The rats must reach SE before they can
be used in CLARITY. Then, the rats underwent transcardial perfusion at 5 mL/minute with 100
mL 1X PBS followed by 30 ml of fresh 4% PFA (Chung et al., 2013). Once the perfusion was
complete, the rat was decapitated and brain removed. The brain was incubated in 10 mL of 4%
PFA for 24 hours at 4°C. The sample size of the study was 2 SE brains and 1 CTRL brain. There
were 3 technical replicates per brain, making the total sample size 9 slices, consisting of 6 SE
slices and 3 CTRL slices.
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Sectioning
The brain was rinsed with 1X PBS five times, shaking for 1 minute in between each rinse. The
brains can be stored in a freezer at this stage until ready for sectioning. The brains that were used
in this study were collected on June 2 and June 15, 2021. The brain was cut into 1 mm thick
slices using a brain matrix and razor blade and transferred into a 24-well plate. The slices were
incubated in 1X PBS for at least 24 hours at 4°C. The slices can be stored for up to 3 months in
this condition.
CLARITY Tissue Clearing Process
HYDROGEL SOLUTION

The X-CLARITY Polymerization Initiator was diluted 100-fold in X-CLARITY Hydrogel
Solution. 2 mL per slice was prepared. Slices were incubated for 24 hours at 4°C in a 12-well
plate. Do not exceed 48 hours of incubation.
Table 1: X-CLARITY Polymerization
Machine Settings

POLYMERIZATION

The polymerization was run using the X-CLARITY
Polymerization machine with the settings shown in Table 1
(Chung et al., 2013). After polymerization, the sample was
shaken on a shaker for 1 minute.
TISSUE CLEARING

The slices were rinsed with 1 mL of 1X PBS five times, shaking for 5 minutes in between each
rinse. The samples can be stored up to 1 week after this
step. The tissue clearing was run using the X-CLARITY
Tissue Clearing machine with the settings shown in Table
2 for 8 hours (Chung et al., 2013). The samples were
checked every 4 hours. The sample could clear faster than
6

Table 2: X-CLARITY Tissue Clearing
Machine Settings

8 hours if the other steps were optimized, so checking at the 4-hour point is crucial. If the
previous steps were not optimized, the sample might need to undergo additional rounds of
clearing. As long as the tissue does not begin to expand or turn yellow, which are signs of over
clearing, then the tissue can be cleared for additional hours if necessary. Then, the sample was
rinsed with 1X PBS five times with shaking for 1 minute in between each rinse. The slices can
be stored for up to 1 week in PBS after undergoing tissue clearing.
Antibody Labeling and Imaging
PRIMARY ANTIBODY

A fresh batch of diluent reagent was prepared using 2.4 g of BSA (6% of final solution), 80 µL
of Triton X-100 (0.2% of final solution), and up to 40 mL of 1X PBS. The diluent was filtered
with a syringe using a 45 µL filter to prevent bacterial growth. The primary antibody was diluted
1:100 and incubated for 1 week at 37°C. There were 4 primary antibodies used in this study that
are listed in Table 3. The Collagen-IV antibody stained the basement membrane on the outside of
the capillaries, GFAP stained astrocytes, Glut-1 stained endothelial cells, and P-gp stained the Pgp efflux transporters in the capillaries (Halliday et al., 1996; Harris et al., 1990; Rahner-Welsch
et al., 1995). After the incubation, the samples were washed with 1mL of washing buffer (0.2%
Triton X-100, 0.02% sodium azide, and PBS) 5 times and was shaken on the shaker for 5
minutes in between each wash. Then, the samples were incubated in the washing buffer for 2
days at 4°C to remove any excess secondary antibody.
SECONDARY ANTIBODY

0.2% Triton X-100 in 5 mL 1X PBS was prepared and secondary antibody was added. The
dilution factor of the secondary antibody is 1:250. The samples were incubated for 3 days at
37°C in the secondary antibody. The secondary antibodies that were used in this study can be
seen in Table 3 across from its primary antibody. After incubation, the samples were washed
7

with 1 mL of washing buffer 5 times, shaking for 5 minutes in between each wash. Then, the
samples were incubated in the washing buffer for 2 days at 4°C to remove any excess secondary
antibody.
IMAGING

Before imaging the samples, they were rinsed with distilled water 3 times, shaking for 5 minutes
in between each rinse. The samples were incubated in mounting solution for one hour, then the
mounting solution was replaced and the samples were incubated for another 1-2 hours. Then,
samples were mounted in glass-bottom dishes and imaged using confocal microscopy. Each
sample was imaged separately on its own glass-bottom dish.
Table 3: Primary and secondary antibody pairings with hosts and dilution factor

RESULTS AND DISCUSSION

Pre-Clearing

Post-Clearing

The purpose of this study was to
develop and optimize the methods of the
CLARITY tissue clearing and imaging
process for CTRL and SE rat brains in
order to visualize potential spatial
differences in the NVU. Conducting this

Figure 2. A brain that has undergone the CLARITY tissue clearing
process. The image on the left is before clearing, and the image on the
right is after clearing has occurred.

study complied with the University of
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Kentucky Laboratory Safety,

CTRL

SE

Chemical Hygiene, Bloodborne
Pathogen and Biological Safety
protocols, as well as the Institutional
Animal Care and Use protocols.
Cleared Tissue
The tissue was fully cleared, and
Figure 3. Col-IV primary antibody images. Col-IV antibody stains the
basement membrane. The basement membrane wraps around capillaries.

therefore, visually transparent
which can be seen in Figure 2. Being

CTRL

SE

able to see through the tissue to the
UK logo in the background
indicates that the lipids were
removed effectively from the tissue.
Images
Since the tissue cleared well, the
images that were obtained had
virtually no background haziness,

Figure 4. GFAP primary antibody images. GFAP stains astrocytes and
astrocytic foot processes. Astrocytic foot processes are the limbs seen branching
off of the astrocytes.

CTRL

allowing for more accurate

SE

quantitative and qualitative
analysis. In the images of ColIV, Glut-1, and P-gp, the
percentage area of antibody
staining appears to be
Figure 5. Glut-1 primary antibody images. Glut-1 stains capillaries.
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CTRL

SE

approximately evenly distributed.
In the GFAP images, the SE
brain appears to have longer
astrocytic foot processes that are
causing the percentage area
staining to be higher in an SE
brain than a CTRL brain.

Figure 6. P-gp primary antibody images. P-gp stains the P-gp efflux transporter
found in capillaries.

Data Analysis
After obtaining images, the images were
quantitatively assessed for percentage area
of antibody staining using ImageJ
software. The images were also
qualitatively assessed for morphological
differences. The data was compiled and
statistically analyzed using Graphpad
Prism. The graphs shown in Figure 7 show
the difference in percentage area of
antibody staining in the CTRL and SE
brains. The only antibody that produced a
statistically significant result in percentage
area staining between groups was GFAP
which could be due to the longer astrocytic
Figure 7. T-test graph for percentage area of antibody
staining. Outliers were removed.

foot processes that are seen in the image. The
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sample size will need to be increased before these findings can be confirmed. Col-IV, Glut-1,
and P-gp did not produce a statistically significant result.
Limitations
One limitation is antibody selection. Antibodies only recognize specific structures, so there is a
possibility that too many or too few structures will be stained if the incorrect antibody is chosen.
This could limit the types of differences that can be visualized. A way to prevent this is to do
extensive research on antibody selection and see which antibodies previous literature indicates
are effective for the desired staining.
Another limitation is tissue clearing. If the tissue is not fully cleared, the images will have a
hazy background which could make differences harder to visualize. A way to prevent this is to
put the tissue through an additional cycle of clearing. As long as the tissue does not start
expanding or turning yellow, it can be cleared again without damage. Another way to prevent
this is to make sure the previous steps of the CLARITY process are optimized, like ensuring
tissue is stored at the proper temperature and incubates for the appropriate amount of time.
A third limitation is over fixation of the brain tissue in PFA. PFA-fixed tissue is
recommended to be incubated in PFA for 24 hours (Howat & Wilson, 2014). Based on previous
literature, if samples are incubated in PFA for more than 24 hours, inconsistent antibody staining
can occur on the outside compared to the middle of a larger section of tissue (Howat & Wilson,
2014). Inconsistent staining throughout the sample will increase the haziness of the background
while imaging. A hazy background can produce images that are completely unusable for
analysis, so ensuring that the samples are incubated in PFA for only 24 hours is crucial to
experimental success.
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A final limitation is the efficacy of the transcardial perfusion. If the brain is not fully
perfused, it cannot be used for CLARITY. During the perfusion, there are indicators to look for
that the brain is perfusing well. These include no fluid coming out of the nose, the lung not
inflating, and the liver staying a red hue. Additionally, the type of drug used to euthanize the rat
is relevant. All of the rats used in this study were euthanized using Fatal Plus. One set of samples
were processed with Euthasol instead of Fatal Plus, but the samples were all unusable for
CLARITY because the brains did not fully perfuse. Euthasol is a phenytoin-based drug, and
phenytoin has been found to negatively weaken the efficacy of brain perfusion in rats even
though all of the other indicators were present that the brain was being well-perfused (Tani et al.,
1995).
CONCLUSIONS
Based on the methods developed in this study, large quantities of rat brain tissue were able to be
cleared using the CLARITY tissue clearing process. Additionally, the antibodies used in this
study did effectively stain the parts of the NVU that were of interest. Since the methods were
effective, a potential morphological difference in astrocytes between a CTRL and SE rat brain
was observed in the images. Also, the graph of GFAP percentage area staining, which was
staining astrocytes, had a statistically significant p-value of 0.029, confirming the qualitative
analysis. Based on the qualitative analysis, this difference could be due to the SE brain having
longer astrocytic foot processes. The sample size of this study is too small to confirm these
results, but now that the methods are developed, the study can be expanded to obtain results with
greater sample size.
Future Directions
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The first future direction for this study is to increase the sample size of this study to at least 3
CTRL and 3 SE brains to ensure the methods are optimized and the data indicates there could be
changes in the neurovascular unit between groups. Another future direction for this study is to
use multi-labeling to stain the whole NVU on one slice instead of using one primary and
secondary antibody to image one part of the NVU. Additionally, examining if there is a
correlation between the levels of immunostaining in the brain and levels in the blood or plasma
could provide more insight into leakage occurring in the BBB. A final future direction for this
research is to apply the methods developed in this study to other neurodegenerative disorders,
like Alzheimer’s disease or other animal models.
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